CI
VIRX

Cowen Inc’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Cowen Inc’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-194
Closed -$33K – 345
2015
Q3 		$33K Sell
194
-48
-20% -$17.3K ﹤0.01% 239
2015
Q2 		$15K Buy
+242
New +$129K ﹤0.01% 451

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Cowen Inc's VIRX Position: Q1 2016 in Review

Cowen Inc sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2016, closing a stake of 357 shares.

Cowen Inc first reported a position in VIRX in Q3 2013 and held it in 7 quarters. The position peaked at $3.3M in Q4 2013. 56 funds tracked by Wall St. Rank hold VIRX as of Q1 2016.

  • Cowen Inc reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Cowen Inc sold 357 Viracta Therapeutics, Inc. Common Stock shares in Q1 2016.
  • Cowen Inc first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 7 quarters.
  • Cowen Inc's Viracta Therapeutics, Inc. Common Stock position peaked at $3.3M in Q4 2013.
  • 56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Cowen Inc's 13F filing for Q1 2016, filed 16 May 2016.